Official position
Director and Chairman, Department of Nuclear Medicine
Institution
Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany
Business address
Liebigstr. 18
04103 Leipzig
Academic education and degrees
1981 - 1988 | MD in Medicine, School of Medicine, Freie Universität Berlin (FU Berlin) |
1989 | Doctoral Dissertation, FU Berlin |
1989 - 1991 | Scientific Researcher, Dept. of Anatomy, University of Bonn |
1991 - 1997 | Residency in Nuclear Medicine, University of Aachen |
1997 | State Examination for physician in nuclear medicine (medical specialist) |
1998 | Venia Legendi (German Habilitation) on the role of PET, SPECT and MRI in vascular dementia, University of Aachen |
2001 | University Professor, Dept. of Nuclear Medicine, University of Leipzig |
Professional career
1989 - 1991 | Scientific Researcher, Dept. of Anatomy, University of Bonn |
1991 - 1996 | Assistant Physician, Dept. of Nuclear Medicine, University of Aachen |
1996 - 1998 | Senior Physician, Dept. of Nuclear Medicine, University of Aachen |
1999 - 2001 | Vice-Head and Vice-Chairman, Dept. of Nuclear Medicine, University of Aachen |
Since Oct. 2001 | Professor, Director and Chairman (C4) of the Dept. of Nuclear Medicine, University of Leipzig, Germany |
May 2008 | Call to the „W3-Professur for Nuclear Medicine, University of Aachen" (declined) |
Honors, awards and positions
1995 | Ludo van Bogaert Award at the International Symposium on SPECT in Clinical Neurology of the World Federation of Neurology, the European Federation of Neurological Societies, and the European Association of Nuclear Medicine (Antwerp, Belgium). |
1999 | Mallinckrodt Award for Nuclear Medicine of the German Association of Nuclear Medicine (DGN) at the 37th International Annual Meeting of the DGN in Ulm, Germany |
1999 | Brahms Award for Thyroid Disease of the DGN at the 37th International Annual Meeting of the DGN in Ulm, Germany |
Since 1999 | Foundation-Member of the inaugural meeting of the Committee for Neuronuclear Medicine of the DGN |
2003 - 2008 | Chairman (President) of the Committee for Neuronuclear Medicine of the DGN |
Since 2003 | Official Member of the Committee „Radiopharmaka" of the DGN |
2005 | KFAS-Prize ("Arabian Nobel Prize") of the Kuwait Foundation for the Advancement of Sciences (KFAS) for the best nuclear medicine researcher of Arabic origin on the occasion of the official prize ceremony held on 5th December 2005 under the patronage of the former Amir of Kuwait Sheikh Jaber Al-Ahmad Al-Jaber Al-Sabah to honour all winners of „Arabian Nobel Prizes". |
Since 2007 | Member of the Expert Commission of Nuclear Medicine in Saxony („Fachkommission Nuklearmedizin der Sächsischen Landesärztekammer") |
2007 - 2009 | Member of the Board of the DGN |
2008 | Congress President of the 46th Annual Meeting of the German Association of Nuclear Medicine (DGN), Leipzig |
2009 - 2011 | Member of the Expert Group on Quality Assurance in Medicine of the German Ministry for the Environment ["Qualitätssicherung in
der Medizin" der Strahlenschutzkommission des Bundesministeriums
für Umwelt, Naturschutz und Reaktorsicherheit (BMU)]
|
Since 2009 | Official Member of the Scientific Board of the Brain Imaging Council
(BIC) of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) |
2011 | First Place SNM Brain Imaging Council Award – Neurosciences Track of the
58th Annual Meeting ot the SNM Advancing Molecular Imaging and
Therapy, San Antonio, Texas, USA |
2012 | Vice President of the BIC, SNMMI |
| 2013 | President of the BIC, SNMMI |
2014 | Kuhl-Lassen Award of the SNMMI at the "61th Annual Meeting of the SNM Advancing Molecular Imaging and Therapy", St. Louis, Missouri, USA |
10 most important peer-reviewed papers (10 out of 370, Scopus h-index: 62)
Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L …O. Sabri. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. Published online July 7, 2020. doi:10.1001/jamaneurol.2020.2526
Sabri O, Meyer PM, Gräf S, Hesse S, Wilke S et al. Cognitive correlates of a4b2 nicotinic acetylcholine receptors in mild Alzheimer's dementia. BRAIN 2018; 141: 1840-1854.
Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B …O. Sabri. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? J Nucl Med. 2016; 57(11): 1740-1745
Sabri O, Becker GA, Meyer PM, Hesse S, Wilke S et al. First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[18F]Flubatine. NeuroImage 2015; 118: 199-208
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akutsu H et al. Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study. Alzheimer´s & Dementia 2015; 11: 964-974
Schroeter ML, Vogt B, Frisch S, Becker G, Barthel H …O. Sabri. Executive deficits are related to the inferior frontal junction in early dementia. Brain 2012; 135(Pt1): 201-215
Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P …O. Sabri. Cerebral amyloid-ß PET with florbetaben(18F) in patients with Alzheimer´s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurology 2011; 10(5): 424-435.
Sabri O, Owega A, Schreckenberger M, Sturz L, Fimm B et al. A truly simultaneous combination of functional transcranial Doppler sonography (fTCD) and 15O-water PET adds fundamental new information on differences in cognitive activation between schizophrenics and healthy control subjects. J Nucl Med 2003; 44: 671-681.
Sabri O, Ringelstein EB, Hellwig D, Schneider R, Schreckenberger M et al. Neuropsychological impairment correlates to hypoperfusion and hypometabolism but not to severity of white matter lesions on MRI in patients with cerebral microangiopathy. Stroke 1999; 30: 556-566
Sabri O, Erkwoh R, Schreckenberger M, Owega A, Sass H, Buell U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 1997; 349: 1735-1739
Foto: Stefan Straube
